Real-world Observational Multi-center Study: Retrospective Analysis of Diagnostic and Treatment Patterns for Stage III–IV Melanoma in Ukraine from 2018 to 2020
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho ER. Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and Therapy. Australia: Exon Publications, 2017. p. 3-22.Search in Google Scholar
Arnold M, De Vries E, Whiteman DC, Jemal A, Bray F, Parkin DM, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer. 2018;143(6):1305-14. https://doi.org/10.1002/ijc.31527 PMid:29659012Search in Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338Search in Google Scholar
Fedorenko Z, Soumkina O, Gorokh Y, Goulak L, Koutsenko L. Cancer in Ukraine 2020-2021. Incidence, mortality, prevalence and other relevant statistics. In: Bulletin of the National Cancer Registry of Ukraine. Ukraine: National Cancer Registry of Ukraine; 2022. p. 86.Search in Google Scholar
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-update. Eur J Cancer. 2022;170:256-84. https://doi.org/10.1016/j.ejca.2022.04.018 PMid:35623961Search in Google Scholar
Michielin O, Van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: Under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1449-61. https://doi.org/10.1016/j.annonc.2020.07.005 PMid:32763452Search in Google Scholar
Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: Under the auspices of the ESMO guidelines committee. Ann Oncol. 2020;31(11):1435-48. https://doi.org/10.1016/j.annonc.2020.07.004 PMid:32763453Search in Google Scholar
Sekulovic LK, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, et al. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. Eur J Cancer. 2017;75:313-22. https://doi.org/10.1016/j.ejca.2017.01.012 PMid:28264791Search in Google Scholar
Carlino M, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002-14. https://doi.org/10.1016/S0140-6736(21)01206-X PMid:34509219Search in Google Scholar
Hoffmann M, Hayoz S, Özdemir BC. Prescription patterns, recurrence, and toxicity rates of adjuvant treatment for stage III/IV melanoma-a real world single-center analysis. Biology (Basel). 2022;11(3):422. https://doi.org/10.3390/biology11030422 PMid:35336796Search in Google Scholar
De Meza M, Ismail RK, Rauwerdink D, Van Not OJ, Van Breeschoten J, Blokx WA. Adjuvant treatment for melanoma in clinical practice-trial versus reality. Eur J Cancer. 2021;158:34-245. https://doi.org/10.1016/j.ejca.2021.08.044 PMid:34600790Search in Google Scholar
Hu HP. Clinical predictors of survival in real-world practice in stage IV melanoma. Cancer Rep (Hoboken). 2023;6(2):e1691. https://doi.org/10.1002/cnr2.1691 PMid:36161287Search in Google Scholar